Clinical trial
Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer
NCT00216203 · Nasser Hanna, M.D., Other · Completed
Key facts
| NCT number | NCT00216203 |
|---|---|
| Title | Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer |
| Official title | A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79 |
| Lead sponsor | Nasser Hanna, M.D., Other |
| Collaborators | Eli Lilly and Company Industry Bristol-Myers Squibb Walther Cancer Institute |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Pemetrexed, Cetuximab |
| Enrollment | 36 |
| Start date | May 1, 2005 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 29, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: